Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

Peter Rossing, Silvio E. Inzucchi, Priya Vart, Niels Jongs, Kieran F. Docherty, Pardeep S. Jhund, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr Ponikowski, Marc S. Sabatine, Scott D. Solomon, David L. DeMets, Olof Bengtsson, Magnus Lindberg, Anna Maria Langkilde, Mikaela Sjöstrand, Bergur V. Stefánsson, Cecilia Karlsson, Glenn M. Chertow, Fan Fan Hou, Ricardo Correa‐Rotter, Robert D. Toto, David C. Wheeler, John J.V. McMurray, Heerspink, HJL